• To reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.

Contraindicated in:

• Hypersensitivity
• Known intolerance
• Angle-closure glaucoma
• Bone marrow depression
• CNS depression
• Severe liver or cardiac disease
• Known or suspected QT interval prolongation
• Lactation: Lactation.

Use Cautiously in:

• Diabetes
• Respiratory insufficiency
• Prostatic hyperplasia
• CNS tumors
• Intestinal obstruction
• Seizures (may lower seizure threshold)
• Concurrent use of benzodiazepines, IV opioids, or volatile anesthetics (may ↑ risk of serious arrhythmias) (use lower initial doses)
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Pedi: Children <2 yr (safety and effectiveness not established)
• Geri: ↑ risk of serious arrhythmias in older adults (use lower initial doses).

Exercise Extreme Caution in:

• Patients with risk factors for prolonged QT syndrome (HF, bradycardia, diuretic use, cardiac hypertrophy, hypokalemia, hypomagnesemia) or other drugs known to prolong QT interval.

CV: hypotension, tachycardia, QT prolongation, ARRHYTHMIAS (INCLUDING TORSADES DE POINTES).

EENT: blurred vision, dry eyes.

GI: constipation, dry mouth.

Neuro: extrapyramidal reactions, abnormal EEG, anxiety, confusion, dizziness, excessive sedation, hallucinations, hyperactivity, mental depression, nightmares, restlessness, SEIZURES, tardive dyskinesia.

Resp: bronchospasm, laryngospasm.

Misc: chills, facial sweating, shivering.

Drug-Drug:

• Additive hypotension with antihypertensives or nitrates.
• Additive CNS depression with other CNS depressants, including alcohol, antihistamines, antidepressants, opioid analgesics, and other sedatives.
• Concurrent use of drugs known to prolong QT interval (↑ risk of potentially life-threatening arrhythmias).

Drug-Natural Products:

• Concomitant use of kava-kava, valerian, chamomile, or hops can ↑ CNS depression.

(Generic available)

• Solution for injection: 2.5 mg/mL;

• IM, IV (Adults): 2.5 mg initially, then additional doses of 1.25 mg may be administered with caution to achieve desired effect.
• IM, IV (Children ≥2 yr): 0.01–0.075 mg/kg (max = 1.25 mg) initially; administer additional doses with extreme caution and only if potential benefit outweighs risks.

Inapsine

• Similar to haloperidol; alters the action of dopamine in the CNS.

• Suppression of nausea and vomiting in selected situations.

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: butyrophenones

Absorption: Well absorbed following IM administration. IV administration results in complete bioavailability.

Distribution: Appears to cross the blood-brain barrier and placenta.

Metabolism/Excretion: Mainly metabolized by the liver. Only 10% excreted unchanged by the kidneys.

Half-life: 2.2 hr.

(sedation)

*Listed as duration of tranquilization; alterations in consciousness may last up to 12 hr.

• Explain purpose of droperidol to patient.
• Caution patient to change positions slowly to minimize orthostatic hypotension.
• Medication causes drowsiness. Advise patient to call for assistance during ambulation and transfer.
• Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during therapy.

droe-PER-i-dole

NDC Code^*

• 0409- Hospira, Inc.
  • 0409-1187- Droperidol
    • 0409-1187-01- 10 AMPULE in 1 CARTON (0409-1187-01) > 2 mL in 1 AMPULE

• 0517- American Regent, Inc.
  • 0517-9702- Droperidol
    • 0517-9702-25- 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9702-25) > 2 mL in 1 VIAL, SINGLE-DOSE